| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2022985 | Regulatory Peptides | 2010 | 5 Pages |
Synthetic organoselenium compounds can be tailored to achieve greater chemopreventive efficacy with minimal toxic side effects by structural modifications. Two organoselenium compounds (Se I and Se II) were synthesized and evaluated for their antihypertensive and therapeutic properties by adrenomedullin (ADM) levels and tyrosine hydroxylase (TH) activity assays in rat heart tissue. 7,12-Dimethylbenz[a]anthracene (DMBA) is known to generate DNA-reactive species during their metabolism, which may enhance oxidative stress in cells. TH is thought to be a rate-limiting enzyme in the biosynthesis of catecholamines. ADM, a potent endogenous vasodilating and natriuretic peptide, may play an important role in the pathophysiology of chronic heart failure. The effects of Se I and Se II were investigated on TH activity, ADM and total RNA levels in the hearts of albino Wistar rats. TH activity was found to be increased significantly by the effect of DMBA (P < 0.05). This increase was restricted in the Se I and Se II treated groups. ADM level was found to be decreased insignificantly by the effect of DMBA (P > 0.05). Total RNA level was found to be decreased significantly by the effect of DMBA (P < 0.05). This study demonstrates that synthetic organoselenium compounds can regulate DMBA-induced stress related changes in rat heart.
